Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia
- First Online:
The objective of post-marketing surveillance of medicines is to rapidly detect adverse drug reactions (ADRs). Early ADR detection will enable policy makers and health professionals to recognise adverse events that may not have been identified in pre-marketing clinical trials. Multiple methods exist for ADR signal detection. Traditional quantitative methods employed in spontaneous reports data have include reporting odds ratio (ROR), proportional reporting ratio (PRR) and Bayesian techniques. With the development of administrative health claims databases, additional methods such as sequence symmetry analysis (SSA) may be able to be employed routinely to confirm ADR signals.
Objective and Method
We tested the time to signal detection of quantitative ADR signalling methods in a health claims database (SSA) and in a spontaneous reporting database (ROR, PRR, Bayesian confidence propagation neural network) for rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure.
This study demonstrated that all four signalling methods detected safety signals within 1–3 years of market entry or subsidisation of the medicines, and for both cases the signals were detected before post-marketing clinical trial results. By contrast, the trial results and subsequent warning or withdrawal were published 5–7 years after first marketing of these medicines.
This case study highlights that a post-marketing quantitative method utilising administrative claims data can be a complementary tool to traditional quantitative methods employed in spontaneous reports that may help to verify safety signals detected in spontaneous reporting data.
- 8.Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Vioxx (rofecoxib). Medicine recall. 2004. http://www.tga.gov.au/safety/recalls-medicine-vioxx-041001.htm. Accessed 10 Jul 2013.
- 9.Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–81.PubMedGoogle Scholar
- 10.United States Department of Health and Human Services, Food and Drug Administration. FDA news release: FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia. 2007. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm. Accessed 2 Dec 2012.
- 11.European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: anti-diabetes medication to be taken off the market. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf. Accessed 20 Dec 2012.
- 12.Australian Government Department of Health and Ageing Therapeutic Goods Administration. Product information, Avandia (rosiglitazone). 2013. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06879-3. Accessed 2 May 2013.
- 13.United States Department of Health and Human Services, Food and Drug Administration. Drugs@FDA. FDA approved drug products. AVANDIA (rosiglitazone maleate) tablets. 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf. Accessed 2 May 2013.
- 28.Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Database of Adverse Event Notifications. 2012. http://www.tga.gov.au/daen/daen-report.aspx. Accessed 26 Nov 2012.
- 29.MedDRA MSSO (Medical Dictionary for Regulatory Activities, Maintenance and Support Services Organization). 2012. http://www.meddra.org/about-meddra/organisation/msso. Accessed 7 Apr 2013.
- 30.Australian Government Department of Health and Ageing Therapeutic Goods Administration. Medical Dictionary for Regulatory Activities-MedDRA. 2013. http://www.tga.gov.au/safety/daen-meddra.htm. Accessed 7 Apr 2013.
- 33.Australian Government Department of Veterans’ Affairs. Treatment population statistics. Quarterly report—March 2011. 2011. http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopMar2011.pdf. Accessed 27 Jul 2011.
- 34.World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification/Defined Daily Dose Index. 2011. http://www.whocc.no/atc_ddd_index/. Accessed 28 Feb 2011.
- 35.Australian Government, Department of Health and Ageing. Schedule of pharmaceutical benefits. PBS for health professional. 2011. http://www.pbs.gov.au/info/healthpro/explanatory-notes/section1/Section_1_2_Explanatory_Notes. Accessed 28 Feb 2011.
- 36.National Centre for Classification in Health. International statistical classification of diseases and related health problems, tenth Revision, Australian modification (ICD-10-AM). Sydney: National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney; 2004.Google Scholar
- 37.Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. 2012. http://www.tga.gov.au/. Accessed 2 Dec 2012.
- 38.United States of Health and Human Services. Food and Drug Administration (FDA). Drugs@FDA. FDA approved drug products. 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name. Accessed 2 Dec 2012.
- 39.Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Australian adverse drug reactions bulletin. 2012. http://www.tga.gov.au/hp/aadrb.htm. Accessed 2 Dec 2012.
- 40.Australian Government. Medicare Australia. Medicare Australia statistics. 2013. https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml. Accessed 3 April 2013.
- 41.Australian Government, Department of Health and Ageing. Australian statistics on medicines. 2012. http://www.pbs.gov.au/info/statistics/asm/asm-2009. Accessed 16 Apr 2013.
- 42.New drugs. Rofecoxib. Aust Prescr. 2000;23:137–9.Google Scholar
- 45.United States Food and Drug Administration. Drug approval package. Voxx (rofecoxib) tablets. Company: Merck Research Laboratories. Application no.: 021042 & 021052. http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_Vioxx.cfm. Accessed 17 May 2013.
- 48.United States Food and Drug Administration. Sequence of events with VIOXX, since opening of IND. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_04_E-FDA-TAB-C.htm. Accessed 17 May 2013.
- 49.United States Food and Drug Administration. NDA 21-042: VIOXX tablets. NDA 21-052: VIOXX oral suspension (rofecoxib). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_01_merck.pdf. Accessed 17 May 2013.
- 50.United States of America, Food and Drug Administration, Centre for Drug Evaluation and Research. Medical review (rofecoxib). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-042S007_Vioxx_medr_P1.pdf. Accessed 16 May 2013.
- 52.NDA 21-042/s007. Vioxx (rofecoxib). Cardiovascular data in Alzheimer’s studies. http://dida.library.ucsf.edu/pdf/oxx01l10. Accessed 16 May 2013.
- 53.United States Department of Health and Human Services, Food and Drug Administration. Vioxx (rofecoxib). 2002. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154520.htm. Accessed 26 Nov 2012.
- 54.Australian Adverse Drug Reactions Bulletin. 2003 Oct;22(5). http://www.tga.gov.au/pdf/aadrb-0310.pdf. Accessed 26 Nov 2012.
- 56.United States Food and Drug Administration, Drugs@FDA, Label and Approval History. Avandia (rosiglitazone maleate). Label. http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21071lbl.pdf. Accessed 18 May 2013.
- 58.United States Department of Health and Human Serviced, Food and Drug Administration. Drug approval package. Avandia (rosiglitazone maleate) tablets. Centre for Drug Evaluation and Research. Application number: 021071. Medical review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21071_Avandia_medr.pdf. Accessed 2 May 2013.
- 59.United States Department of Health and Human Services, Food and Drug Administration. Drugs@FDA, FDA approved drug products. Prescribing information Avandia. http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21071lbl.pdf. Accessed 26 Jun 2013.
- 60.Australian Government, Department of Health and Ageing, Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG). https://www.ebs.tga.gov.au/. Accessed 21 Dec 2012.
- 61.Australian Government, Department of Veterans’ Affairs, Veterans’ Affairs Pharmaceutical Advisory Centre (VAPAC). http://www.dva.gov.au/service_providers/pharmacy/Pages/vapac.aspx. Accessed 2 May 2013.
- 62.United States Department of Health and Human Services, Food and Drug Administration (FDA). Safety. Avandia (rosiglitazone) April 2002. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154468.htm. Accessed 2 Dec 2012.
- 63.United States Department of Health and Human Services. Food and Drug Administration (FDA). Safety: summary-FDA April 2002, ACTOS [pioglitazone HCl]; AVANDIA [rosiglitazone maleate]. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM170872.pdf. Accessed 7 Dec 2012.
- 64.Felix B, editor. Australian medicines handbook 2002. Adelaide: Australian Medicines Handbook Pty Ltd; 2002.Google Scholar
- 65.Australian Government, Department of Health and Ageing, Therapeutic Goods and Administration. Australia adverse drug reactions bulletin, vol. 22, no. 2. http://www.tga.gov.au/hp/aadrb-0304.htm. Accessed 2 Dec 2012.
- 66.GlaxoSmithKline. Press release: Avandia receives PBS listing. http://www.gsk.com.au/resources.ashx/MediaCentreChildDataAssociatedDownloads/31/File/C974E854090FD80DD9CF0E0F94D0C943/Avandia_Press_release_20031124.pdf. Accessed 2 Dec 2012.
- 67.National Prescribing Service Limited. Early use of insulin and oral antidiabetic agents. http://www.nps.org.au/__data/assets/pdf_file/0014/35231/PPR40_insulin_and_oral_antidiabetic_drugs_0308.pdf. Accessed 2 Dec 2012.
- 68.United States Department of Health and Human Services, Food and Drug Administration (FDA). Information for healthcare professionals rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm. Accessed 7 Dec 2012.
- 69.Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–105.Google Scholar
- 70.Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89.PubMedCrossRefGoogle Scholar
- 71.Glaxo Smith Kline. Study no 049653/211 a 52 week double blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes and congestive heart failure. http://ctr.gsk.co.uk/Summary/Rosiglitazone/IV_49653_211.pdf. Accessed 2 May 2013.
- 72.Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;29:2007.Google Scholar
- 73.Therapeutic Good Administration eBusiness Services. Product and consumer medicine information. Product information Avandia (rosiglitazone). https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06879-3. Accessed 2 May 2013.
- 74.Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002;89(2):204–9.PubMedCrossRefGoogle Scholar
- 80.United States Department of Health and Human Services. Drugs at FDA: FDA approved drug products. Vioxx (rofecoxib). NDA 21-042 (capsules) and NDA 21-052 (oral solution). http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021042_52_vioxx_medr_P1.pdf. Accessed 10 Jul 2013.